查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1178085

Reiter症候群治療的全球市場:各藥物類型，各劑型，各給藥途徑，各流通管道，各終端用戶，各地區─產業規模，佔有率，趨勢，競爭，機會，預測，競爭(2017年～2027年)

Reiter's Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Drug Type, By Dosage Form, By Route of Administration, By Distribution Channel, By End User, By Region
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球Reiter症候群治療的市場規模在預測期間(2023年～2027年)中預計將以穩定的年複合成長率成長。

急速增加的反應性關節炎，對其有效的治療的需求提升，醫療產業的進步，促進了市場的成長。

本報告提供全球Reiter症候群治療市場相關調查分析，提供產品概要，市場展望，競爭情形等系統性資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 COVID-19對全球Reiter症候群治療市場帶來的影響

第4章 摘要整理

第5章 VOC (客戶的迴響)

  • 偏好:各藥物類型
  • Reiter症候群治療的需求提高要素
  • 對Reiter症候群治療的採用的障礙
  • 品牌認知度

第6章 臨床試驗

  • 進行中的臨床試驗
  • 完成的臨床試驗
  • 中斷的臨床試驗
  • 臨床試驗分析

第7章 專利分析

  • 取得專利的(2016年～2020年)
  • 專利申請

第8章 全球Reiter症候群治療市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各藥物類型(抗生素，皮質類固醇，非類固醇消炎劑(NSAID)，免疫抑製藥，其他)
    • 各劑型(錠劑，注射劑，其他)
    • 各給藥途徑(口服，靜脈內，其他)
    • 各流通管道(零售藥局，醫院藥局，線上藥局)
    • 各終端用戶(醫院·診所，門診病人治療中心，其他)
    • 各企業(2021年)
    • 各地區
  • 產品市場地圖

第9章 北美的Reiter症候群治療市場展望

第10章 歐洲的Reiter症候群治療市場展望

第11章 亞太地區的Reiter症候群治療市場展望

第12章 南美的Reiter症候群治療市場展望

第13章 中東及非洲的Reiter症候群治療市場展望

第14章 市場動態

  • 促進因素
  • 課題

第15章 市場趨勢與開發

第16章 競爭情形

  • F. Hoffmann-La Roche AG
  • Pfizer, Inc.
  • Novartis AG
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Abbott Laboratories, Inc.
  • GlaxoSmithKline plc
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • AstraZeneca, Plc.

第17章 策略性建議

第18章 關於本公司·免責聲明

簡介目錄
Product Code: 8217

Global Reiter's syndrome treatment market is projected to register CAGR growth in the forecast years, 2023-2027 on the account of growth factors like increasing instances of reactive arthritis, along with the advancement of the treatment processes and methods. Moreover, advancing healthcare industry for the better availability of the patient care suffering from severe conditions like reactive arthritis, is also responsible for the growth of the global Reiter's syndrome treatment market in the upcoming five years.

Reiter's syndrome is also known as reactive arthritis, which is a form of inflammatory arthritis. It is the joint disease that causes painful inflammations. The disease is a reaction to a bacterial infection. These bacteria are often found in genitals like Chlamydia trachomatis or in bowel like Campylobacter, Salmonella, Shigella and Yersinia. Genital bacteria transmit through sex and usually does not show major symptoms. In certain cases, a pus-like or watery discharge from the genitals is observed. Whereas bowel bacteria usually cause diarrhea along with discharge and can be considered as minor symptoms of Reiter's syndrome.

Increasing Instances of Reiter's Syndrome Drives Market Growth

Rapidly increasing instances of reactive arthritis and surging demand for the effective treatment of the same in driving the growth of the global Reiter's syndrome treatment market in the upcoming five years. Reactive arthritis is a rare form of arthritis when compared to other forms of arthritis. More than 350 million patients of arthritis are currently suffering as of 2021 in the entire world. According to CDC, In the United States, 24% of all adults, or 58.5 million people, have arthritis. 1 in every 4 adults has arthritis and reports severe joint pain.

Whereas twenty-seven per 100,000 population globally suffers from Reiter's syndrome, that majorly affects the adult males between 20-40 years of age. Growing population, increasing instances of unprotected sexual intercourse, increase the chances of the population contracting the disease and thus aiding to the growth of the global Reiter's syndrome treatment market in the next five years.

Market Segmentation

The global Reiter's syndrome treatment market segmentation is based on drug type, dosage form, route of administration, distribution channel, end user, regional distribution, and competitive landscape. Drug type market segment is further fragmented into antibiotics, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressive drugs, and others. Based on dosage form, the market is sub-segmented into tablets, injections, and others. Market segmentation on the basis of route of administration, is further bifurcated into oral, intravenous, and others. Distribution channel segment is differentiated further among retail pharmacies, hospital pharmacies, and online pharmacies. The end user segment analysis the market fragments among hospitals & clinics, ambulatory care centers, and others. The market analysis also studies the regional segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

F. Hoffmann-La Roche AG, Pfizer, Inc., Novartis AG, Cipla Inc., Dr. Reddy's Laboratories Ltd., Abbott Laboratories, Inc., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd, AstraZeneca, Plc., are enlisted in a partial list of major market players of the global Reiter's syndrome treatment market.

Report Scope:

In this report, global Reiter's syndrome treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Reiter's Syndrome Treatment Market, By Drug Type:

Antibiotics

Corticosteroids

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Immunosuppressive Drugs

Others

  • Reiter's Syndrome Treatment Market, By Dosage Form:

Tablets

Injections

Others

  • Reiter's Syndrome Treatment Market, By Route of Administration:

Oral

Intravenous

Others

  • Reiter's Syndrome Treatment Market, By Distribution Channel:

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

  • Reiter's Syndrome Treatment Market, By End User:

Hospitals & Clinics

Ambulatory Care Centers

Others

  • Reiter's Syndrome Treatment Market, By Region:

North America

  • United States
  • Mexico
  • Canada

Europe

  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Reiter's syndrome treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Reiter's Syndrome Treatment Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Preference, By Drug Type
  • 5.2. Factors Contributing to Higher Demand of Reiter's Syndrome Treatment
  • 5.3. Barriers to Adoption of Reiter's Syndrome Treatment
  • 5.4. Brand Awareness

6. Clinical Trials

  • 6.1. Ongoing Clinical Trials
  • 6.2. Completed Clinical Trials
  • 6.3. Terminated Clinical Trials
  • 6.4. Clinical Trial Analysis

7. Patent Analysis

  • 7.1. Patent Granted (2016-2020)
  • 7.2. Patent Applications Filed

8. Global Reiter's Syndrome Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type (Antibiotics, Corticosteroids, Nonsteroidal anti-inflammatory drugs (NSAIDs), Immunosuppressive Drugs, Others)
    • 8.2.2. By Dosage Form (Tablets, Injections, Others)
    • 8.2.3. By Route of Administration (Oral, Intravenous, Others)
    • 8.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 8.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 8.2.6. By Company (2021)
    • 8.2.7. By Region
  • 8.3. Product Market Map

9. North America Reiter's Syndrome Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Dosage Form
    • 9.2.3. By Route of Administration
    • 9.2.4. By Distribution Channel
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Reiter's Syndrome Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Dosage Form
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
        • 9.3.1.2.5. By End User
    • 9.3.2. Mexico Reiter's Syndrome Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Dosage Form
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
        • 9.3.2.2.5. By End User
    • 9.3.3. Canada Reiter's Syndrome Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Dosage Form
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel
        • 9.3.3.2.5. By End User

10. Europe Reiter's Syndrome Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Dosage Form
    • 10.2.3. By Route of Administration
    • 10.2.4. By Distribution Channel
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. Europe: Country Analysis
    • 10.3.1. France Reiter's Syndrome Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Dosage Form
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Distribution Channel
        • 10.3.1.2.5. By End User
    • 10.3.2. Germany Reiter's Syndrome Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Dosage Form
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Distribution Channel
        • 10.3.2.2.5. By End User
    • 10.3.3. United Kingdom Reiter's Syndrome Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Dosage Form
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Distribution Channel
        • 10.3.3.2.5. By End User
    • 10.3.4. Italy Reiter's Syndrome Treatment Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Drug Type
        • 10.3.4.2.2. By Dosage Form
        • 10.3.4.2.3. By Route of Administration
        • 10.3.4.2.4. By Distribution Channel
        • 10.3.4.2.5. By End User
    • 10.3.5. Spain Reiter's Syndrome Treatment Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Drug Type
        • 10.3.5.2.2. By Dosage Form
        • 10.3.5.2.3. By Route of Administration
        • 10.3.5.2.4. By Distribution Channel
        • 10.3.5.2.5. By End User

11. Asia-Pacific Reiter's Syndrome Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Type
    • 11.2.2. By Dosage Form
    • 11.2.3. By Route of Administration
    • 11.2.4. By Distribution Channel
    • 11.2.5. By End User
    • 11.2.6. By Country
  • 11.3. Asia-Pacific: Country Analysis
    • 11.3.1. China Reiter's Syndrome Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Type
        • 11.3.1.2.2. By Dosage Form
        • 11.3.1.2.3. By Route of Administration
        • 11.3.1.2.4. By Distribution Channel
        • 11.3.1.2.5. By End User
    • 11.3.2. India Reiter's Syndrome Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Type
        • 11.3.2.2.2. By Dosage Form
        • 11.3.2.2.3. By Route of Administration
        • 11.3.2.2.4. By Distribution Channel
        • 11.3.2.2.5. By End User
    • 11.3.3. South Korea Reiter's Syndrome Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Type
        • 11.3.3.2.2. By Dosage Form
        • 11.3.3.2.3. By Route of Administration
        • 11.3.3.2.4. By Distribution Channel
        • 11.3.3.2.5. By End User
    • 11.3.4. Japan Reiter's Syndrome Treatment Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Drug Type
        • 11.3.4.2.2. By Dosage Form
        • 11.3.4.2.3. By Route of Administration
        • 11.3.4.2.4. By Distribution Channel
        • 11.3.4.2.5. By End User
    • 11.3.5. Australia Reiter's Syndrome Treatment Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Drug Type
        • 11.3.5.2.2. By Dosage Form
        • 11.3.5.2.3. By Route of Administration
        • 11.3.5.2.4. By Distribution Channel
        • 11.3.5.2.5. By End User

12. South America Reiter's Syndrome Treatment Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Drug Type
    • 12.2.2. By Dosage Form
    • 12.2.3. By Route of Administration
    • 12.2.4. By Distribution Channel
    • 12.2.5. By End User
    • 12.2.6. By Country
  • 12.3. South America: Country Analysis
    • 12.3.1. Brazil Reiter's Syndrome Treatment Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Drug Type
        • 12.3.1.2.2. By Dosage Form
        • 12.3.1.2.3. By Route of Administration
        • 12.3.1.2.4. By Distribution Channel
        • 12.3.1.2.5. By End User
    • 12.3.2. Argentina Reiter's Syndrome Treatment Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Drug Type
        • 12.3.2.2.2. By Dosage Form
        • 12.3.2.2.3. By Route of Administration
        • 12.3.2.2.4. By Distribution Channel
        • 12.3.2.2.5. By End User
    • 12.3.3. Colombia Reiter's Syndrome Treatment Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Drug Type
        • 12.3.3.2.2. By Dosage Form
        • 12.3.3.2.3. By Route of Administration
        • 12.3.3.2.4. By Distribution Channel
        • 12.3.3.2.5. By End User

13. Middle East and Africa Reiter's Syndrome Treatment Market Outlook

  • 13.1. Market Size & Forecast
    • 13.1.1. By Value
  • 13.2. Market Share & Forecast
    • 13.2.1. By Drug Type
    • 13.2.2. By Dosage Form
    • 13.2.3. By Route of Administration
    • 13.2.4. By Distribution Channel
    • 13.2.5. By End User
    • 13.2.6. By Country
  • 13.3. MEA: Country Analysis
    • 13.3.1. South Africa Reiter's Syndrome Treatment Market Outlook
      • 13.3.1.1. Market Size & Forecast
        • 13.3.1.1.1. By Value
      • 13.3.1.2. Market Share & Forecast
        • 13.3.1.2.1. By Drug Type
        • 13.3.1.2.2. By Dosage Form
        • 13.3.1.2.3. By Route of Administration
        • 13.3.1.2.4. By Distribution Channel
        • 13.3.1.2.5. By End User
    • 13.3.2. Saudi Arabia Reiter's Syndrome Treatment Market Outlook
      • 13.3.2.1. Market Size & Forecast
        • 13.3.2.1.1. By Value
      • 13.3.2.2. Market Share & Forecast
        • 13.3.2.2.1. By Drug Type
        • 13.3.2.2.2. By Dosage Form
        • 13.3.2.2.3. By Route of Administration
        • 13.3.2.2.4. By Distribution Channel
        • 13.3.2.2.5. By End User
    • 13.3.3. UAE Reiter's Syndrome Treatment Market Outlook
      • 13.3.3.1. Market Size & Forecast
        • 13.3.3.1.1. By Value
      • 13.3.3.2. Market Share & Forecast
        • 13.3.3.2.1. By Drug Type
        • 13.3.3.2.2. By Dosage Form
        • 13.3.3.2.3. By Route of Administration
        • 13.3.3.2.4. By Distribution Channel
        • 13.3.3.2.5. By End User

14. Market Dynamics

  • 14.1. Drivers
  • 14.2. Challenges

15. Market Trends & Developments

16. Competitive Landscape

  • 16.1. F. Hoffmann-La Roche AG
  • 16.2. Pfizer, Inc.
  • 16.3. Novartis AG
  • 16.4. Cipla Inc.
  • 16.5. Dr. Reddy's Laboratories Ltd.
  • 16.6. Abbott Laboratories, Inc.
  • 16.7. GlaxoSmithKline plc
  • 16.8. Sun Pharmaceutical Industries Ltd
  • 16.9. Teva Pharmaceutical Industries Ltd
  • 16.10. AstraZeneca, Plc.

17. Strategic Recommendations

18. About Us & Disclaimer